WuXi PharmaTech Breaks Ground on New Cell Therapy Manufacturing Facility
Apr 29, 2014
The new facility will consist of 45,000 square feet of clinical and commercial manufacturing space and will supplement WuXi's existing 16,000-square-foot cGMP cell therapy manufacturing facility. This expansion will support growing customer demand with single-source contract development and cGMP manufacture capabilities for allogeneic and autologous cell-based therapeutics. The new facility will be built using advanced modular design, with flexible clean room technology, disposable equipment, and microcarrier cell culture systems.
Located in the Philadelphia Navy Yard, the new facility will complement WuXi's existing facility and capabilities which include analytical chemistry, cell banking, cell characterization, molecular biology and lot release testing, thereby providing fully integrated services for cell therapies in
"Cell therapies offer important treatment options, and WuXi is committed to bringing them to patients faster," said Dr.
For more information on WuXi's services in the manufacture of cell therapies, please visit http://www.wuxiapptec.com/bio_cgmpManufactureOfCellularTherapeutics.html.
For more information, please contact:
Director of Investor Relations
+1 (201) 585-2048
Associate Director of Corporate Communications